Medicure Inc.(MPH)

Description: Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.

---

Keywords: Medicine Pharmaceutical Biopharmaceutical Organ Systems Clinic Disorders Pharma Neurological Disorders Cardiology Skin Transdermal Piperidines Acute Coronary Syndrome Tardive Dyskinesia Gpiib/Iiia Inhibitors Tardive Biopharmaceutical Industry Segment Glycoprotein Iib/Iiia Glycoprotein Iib/Iiia Inhibitors Tirofiban Treatment Of Acute Coronary Syndrome

---

Home Page: www.medicure.com

MPH Technical Analysis

2-1250 Waverley Street
Winnipeg, MB R3T 6C6
Canada
Phone: 204 487 7412

---

Officers

Exchange: V

Country: CA : Canada

Currency: Canadian Dollar (C$)